At the ESMO 2026 Congress, new data from the Phase 3 RASolute 302 trial showed that Revolution Medicines' daraxonrasib doubled median overall survival to 13.2 months across diverse RAS mutation subgroups in advanced pancreatic cancer. Meanwhile, Tango Therapeutics announced an 82% response rate for its vopimetostat and daraxonrasib combination, while Nature Medicine reported Phase 2 results for the camupepimut vaccine. Patient advocates highlighted ongoing healthcare access barriers despite these advancements.
Daraxonrasib RASolute 302 trial survival results
- ▪In the Phase 3 RASolute 302 trial, patients with previously treated metastatic pancreatic cancer receiving daraxonrasib lived a median of 13.2 months compared to 6.7 months for chemotherapy.
- ▪The survival benefit of daraxonrasib in the RASolute 302 trial was consistent across various RAS mutation types, non-mutated RAS tumors, and differing comparator chemotherapy regimens.
- ▪A Phase 3 trial analysis presented by Dr. Zev Wainberg at ESMO 2026 demonstrated that daraxonrasib improved survival compared with standard chemotherapy across multiple patient groups with advanced pancreatic cancer.
Senaha family clinical trial experience
- ▪Clinical trial advocate Dana Senaha noted that FDA approval of daraxonrasib does not guarantee equitable access for patients lacking financial resources, flexible jobs, or nearby specialized cancer centers.
- ▪During clinical trial treatment with daraxonrasib, trial participant Bobby Senaha experienced side effects including skin rash, fingernail inflammation, and intermittent gastrointestinal issues while reducing oral pain medication.
- ▪Participating in the daraxonrasib clinical trial required the Senaha family to travel between Hawaii and San Antonio every 21 days for clinic visits, scans, and treatments.
Tango Therapeutics vopimetostat combination development
- ▪In a Phase 1/2 trial of vopimetostat and daraxonrasib, dose level 1 (200mg/600mg daily) was well-tolerated, whereas dose level 2 (250mg/600mg daily) caused dose-limiting toxicities in 3 of 4 patients.
- ▪Tango Therapeutics announced plans to launch a Phase 3 trial comparing vopimetostat plus daraxonrasib against chemotherapy in first-line pancreatic cancer patients with MTAP deletions in early 2027.
- ▪Tango Therapeutics deprioritized novel target discovery and eliminated 14% of its workforce, affecting approximately 19 R&D staff, to fund its frontline pancreatic cancer pivotal trial.
- ▪Tango Therapeutics reported an updated 82% objective response rate in 22 evaluable pancreatic cancer patients receiving investigational PRMT5 inhibitor vopimetostat combined with daraxonrasib.
Camupepimut results in AMPLIFY-7P trial
- ▪High-resolution HLA typing in the AMPLIFY-7P trial demonstrated that camupepimut induced mKRAS-specific T-cell immunity regardless of individual patient HLA allele profiles.
- ▪Patients receiving camupepimut in the AMPLIFY-7P trial showed a 14.0% disease-free survival advantage at 6 months during the active dosing period compared to standard-of-care observation.
- ▪In the Phase 2 AMPLIFY-7P trial, camupepimut did not meet its primary disease-free survival endpoint in Stage I-III KRAS-mutated pancreatic adenocarcinoma patients, showing median DFS of 23.8 versus 21.2 months.
- ▪Camupepimut-induced mKRAS-specific T-cell responses greater than 9.17-fold over baseline occurred in 82.2% of treated patients and significantly correlated with improved disease-free survival.
RAS mutations and daraxonrasib mechanism
- ▪More than 90% of pancreatic cancers carry mutations in RAS genes, which continuously drive active cell growth and tumor development.
- ▪Daraxonrasib is an oral targeted therapy designed to inhibit both mutated and nonmutated active forms of the RAS protein.
Story comments
Loading comments…